ClinicalTrials.gg
CompletedNCT01426386Updated Nov 17, 2020Results posted

A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment

A Phase 2 interventional study of FE 999049 and Gonal - F in Infertility, sponsored by Ferring Pharmaceuticals. Completed at 8 sites in 4 countries. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2020-11-17.

Sponsored by Ferring Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
18 Years to 37 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing follitropin delta in Infertility — 1 open to participants now, 1 under way, none of them phase 3. follitropin delta · Infertility.

Enrollment
6th of 13
265 · median 220
Started
2011
the only one that year
Phase 2
5 of 13
1 open now
Registered
1st of 13
by date
Lead sponsor
10 of 13
Ferring Pharmaceuticals

Among the 13 studies testing follitropin delta in Infertility, this one is the 6th largest by enrollment, is the only one that started in 2011, is one of 5 in phase 2, and was the 1st registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 13 studies testing follitropin delta in Infertility is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About follitropin delta

follitropin delta: first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 37 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing follitropin delta in Infertility, or all of them as a file.
02

Study summary

This trial investigates the effects of several doses of FE 999049 in women undergoing IVF/ICSI (in-vitro fertilisation/intracytoplasmic sperm injection) treatment.

03

Conditions studied

  • Infertility

Browse trials for

04

Who can participate

Ages eligible
18 Years to 37 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women diagnosed with tubal infertility, unexplained infertility, infertility related to endometriosis stage I/II or with partners diagnosed with male factor infertility
  • Women eligible for IVF (in-vitro fertilisation) and/or ICSI (intracytoplasmic sperm injection) treatment
  • Women aged 18-37 years
  • Women with (BMI) of 18.5-32.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Women with polycystic ovary syndrome (PCOS) associated with anovulation, endometriosis stage III/IV
  • Women with history of recurrent miscarriage
  • Women with to controlled ovarian stimulation with gonadotropins
  • Women with three or more controlled ovarian stimulation cycles
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
265 participants (actual)

Study arms

  • Experimental
    5.2 µg

    Drug: FE 999049

  • Experimental
    6.9 µg

    Drug: FE 999049

  • Experimental
    8.6 µg

    Drug: FE 999049

  • Experimental
    10.3 µg

    Drug: FE 999049

  • Experimental
    12.1 µg

    Drug: FE 999049

  • Active comparator
    11 µg FbM (150 IU)

    Drug: Gonal - F

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Oocytes Retrieved

    Time frame: Day of oocyte retrieval (up to Day 18 after start of stimulation)

Secondary outcomes

  1. Number and Size of Follicles During Stimulation

    Follicular volume at end of stimulation

    Time frame: End of stimulation (up to 16 stimulation days)

  2. Endocrine Profile

    Estradiol at end of stimulation

    Time frame: End of stimulation (up to 16 stimulation days)

  3. Total IMP Dose

    Time frame: End of stimulation (up to 16 stimulation days)

  4. Number of Fertilised Oocytes

    An oocyte with 2 pronuclei was regarded as correctly fertilised

    Time frame: Day 1 after insemination

  5. Number and Quality of Blastocysts on Day 5

    Number of blastocysts (total and good-quality) on Day 5 are presented. A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher

    Time frame: Day 5 after oocyte retrieval

  6. Clinical Pregnancy With Fetal Heart Beat Rate

    Clinical pregnancy with fetal heart beat was defined as at least one intrauterine gestational sac with fetal heart beat

    Time frame: 5-6 weeks after transfer

  7. Frequency and Intensity of Adverse Events

    Time frame: From signing informed consent form until end of trial visit (up to 5 months)

07

Results

Posted Aug 3, 2018

Participant flow

A total of 7 sites randomised subjects to the trial: 1 in Belgium, 1 in Czech Republic, 1 in Denmark and 4 in Spain.

Participant flow — Overall Study
MilestoneFE 999049 5.2 µgFE 999049 6.9 µgFE 999049 8.6 µgFE 999049 10.3 µgFE 999049 12.1 µgGONAL-F 11 µg
Started424544444743
Completed393942444342
Not completed362041
Withdrew: Adverse event010000
Withdrew: Did not attend scheduled visit140021
Withdrew: Poor response212010
Withdrew: Personal reasons000010

Outcome measures

PrimaryNumber of Oocytes Retrieved
Time frame:
Day of oocyte retrieval (up to Day 18 after start of stimulation)
Reported as:
Mean · Oocytes
Number of Oocytes Retrieved
OocytesFE 999049 5.2 µgFE 999049 6.9 µgFE 999049 8.6 µgFE 999049 10.3 µgFE 999049 12.1 µgGONAL-F 11 µg
Number of Oocytes Retrieved5.2 ± 3.37.9 ± 5.99.2 ± 4.610.5 ± 7.012.2 ± 5.910.4 ± 5.2
Statistical analysis
  • FE 999049 5.2 µg vs FE 999049 6.9 µg vs FE 999049 8.6 µg vs FE 999049 10.3 µg vs FE 999049 12.1 µg · ANCOVA · p = <0.001 (The a priori threshold for statistical significance was 5% (two-sided)) · Slope of the dose-response curve: 7.9 · 95% CI 5.69 to 10.18Number of oocytes retrieved as dependent variable, centre and AMH strata (5.0-14.9 pmol/L and 15.0-44.9 pmol/L) as factors and log(dose) as covariate
SecondaryNumber and Size of Follicles During Stimulation

Follicular volume at end of stimulation

Time frame:
End of stimulation (up to 16 stimulation days)
Reported as:
Mean · cm^3
Number and Size of Follicles During Stimulation
cm^3FE 999049 5.2 µgFE 999049 6.9 µgFE 999049 8.6 µgFE 999049 10.3 µgFE 999049 12.1 µgGONAL-F 11 µg
Number and Size of Follicles During Stimulation19.2 ± 7.023.0 ± 10.525.0 ± 9.227.9 ± 15.628.2 ± 9.526.7 ± 9.2
Statistical analysis
  • FE 999049 5.2 µg vs FE 999049 6.9 µg vs FE 999049 8.6 µg vs FE 999049 10.3 µg vs FE 999049 12.1 µg · ANCOVA · p = <0.001 (No adjustment for multiplicity was applied for the secondary endpoints) · Slope of the dose-response curve: 11.1 · 95% CI 6.78 to 15.48Follicular volume as dependent variable, centre and AMH strata (5.0-14.9 pmol/L and 15.0-44.9 pmol/L) as factors and log(dose) as covariate
SecondaryEndocrine Profile

Estradiol at end of stimulation

Time frame:
End of stimulation (up to 16 stimulation days)
Reported as:
Mean · pmol/L
Endocrine Profile
pmol/LFE 999049 5.2 µgFE 999049 6.9 µgFE 999049 8.6 µgFE 999049 10.3 µgFE 999049 12.1 µgGONAL-F 11 µg
Endocrine Profile3641.9 ± 2954.65221.1 ± 3378.85689.5 ± 3995.76171.8 ± 3855.96442.0 ± 3195.25750.7 ± 3709.7
Statistical analysis
  • FE 999049 5.2 µg vs FE 999049 6.9 µg vs FE 999049 8.6 µg vs FE 999049 10.3 µg vs FE 999049 12.1 µg · ANCOVA · p = <0.001 (No adjustment for multiplicity was applied for the secondary endpoints) · Slope of the dose-response curve: 0.8 · 95% CI 0.56 to 1.11Log(estradiol) as dependent variable, AMH strata (5.0-14.9 pmol/L and 15.0-44.9 pmol/L) as factor, log(dose) and log(baseline estradiol) as covariates
SecondaryTotal IMP Dose
Time frame:
End of stimulation (up to 16 stimulation days)
Reported as:
Mean · µg
Total IMP Dose
µgFE 999049 5.2 µgFE 999049 6.9 µgFE 999049 8.6 µgFE 999049 10.3 µgFE 999049 12.1 µgGONAL-F 11 µg
Total IMP Dose50.0 ± 11.661.9 ± 13.771.9 ± 14.181.0 ± 14.297.8 ± 22.094.7 ± 18.1
SecondaryNumber of Fertilised Oocytes

An oocyte with 2 pronuclei was regarded as correctly fertilised

Time frame:
Day 1 after insemination
Reported as:
Mean · Fertilised oocytes
Number of Fertilised Oocytes
Fertilised oocytesFE 999049 5.2 µgFE 999049 6.9 µgFE 999049 8.6 µgFE 999049 10.3 µgFE 999049 12.1 µgGONAL-F 11 µg
Number of Fertilised Oocytes3.7 ± 2.55.4 ± 3.84.9 ± 2.76.1 ± 5.16.7 ± 3.56.4 ± 3.5
Statistical analysis
  • FE 999049 5.2 µg vs FE 999049 6.9 µg vs FE 999049 8.6 µg vs FE 999049 10.3 µg vs FE 999049 12.1 µg · ANCOVA · p = <0.001 (No adjustment for multiplicity was applied for the secondary endpoints) · Slope of the dose-response curve: 3.2 · 95% CI 1.71 to 4.78Fertilised oocytes as dependent variable, AMH strata (5.0-14.9 pmol/L and 15.0-44.9 pmol/L) as factor and log(dose) as covariate
SecondaryNumber and Quality of Blastocysts on Day 5

Number of blastocysts (total and good-quality) on Day 5 are presented. A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher

Time frame:
Day 5 after oocyte retrieval
Reported as:
Mean · Blastocysts
Number and Quality of Blastocysts on Day 5
BlastocystsFE 999049 5.2 µgFE 999049 6.9 µgFE 999049 8.6 µgFE 999049 10.3 µgFE 999049 12.1 µgGONAL-F 11 µg
Total blastocysts2.3 ± 1.73.1 ± 2.72.7 ± 2.02.8 ± 2.83.2 ± 2.23.5 ± 2.5
Good quality blastocysts0.9 ± 1.21.4 ± 1.71.2 ± 1.21.4 ± 1.51.3 ± 1.31.6 ± 1.6
SecondaryClinical Pregnancy With Fetal Heart Beat Rate

Clinical pregnancy with fetal heart beat was defined as at least one intrauterine gestational sac with fetal heart beat

Time frame:
5-6 weeks after transfer
Reported as:
Number · percentage
Clinical Pregnancy With Fetal Heart Beat Rate
percentageFE 999049 5.2 µgFE 999049 6.9 µgFE 999049 8.6 µgFE 999049 10.3 µgFE 999049 12.1 µgGONAL-F 11 µg
Clinical Pregnancy With Fetal Heart Beat Rate36 (21.6 to 52.0)40 (25.7 to 55.7)36 (22.4 to 52.2)25 (13.2 to 40.3)40 (26.4 to 55.7)51 (35.5 to 66.7)
Statistical analysis
  • FE 999049 5.2 µg vs FE 999049 6.9 µg vs FE 999049 8.6 µg vs FE 999049 10.3 µg vs FE 999049 12.1 µg vs GONAL-F 11 µg · Chi-squared · p = 0.248 (No adjustment for multiplicity was applied for the secondary endpoints)
SecondaryFrequency and Intensity of Adverse Events
Time frame:
From signing informed consent form until end of trial visit (up to 5 months)
Reported as:
Number · participants
Frequency and Intensity of Adverse Events
participantsFE 999049 5.2 µgFE 999049 6.9 µgFE 999049 8.6 µgFE 999049 10.3 µgFE 999049 12.1 µgGONAL-F 11 µg
Any mild adverse events151717181511
Any moderate adverse events265982
Any severe adverse events000100

Adverse events

Collected over From signing informed consent form until the end of trial visit (up to 5 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FE 999049 5.2 µg0/42 (0%)0/42 (0%)11/42 (26.2%)
FE 999049 6.9 µg0/45 (0%)0/45 (0%)9/45 (20%)
FE 999049 8.6 µg0/44 (0%)0/44 (0%)11/44 (25%)
FE 999049 10.3 µg0/44 (0%)1/44 (2.3%)12/44 (27.3%)
FE 999049 12.1 µg0/47 (0%)0/47 (0%)11/47 (23.4%)
GONAL-F 11 µg0/43 (0%)0/43 (0%)4/43 (9.3%)
Most frequent serious events
Most frequent serious events
EventFE 999049 5.2 µgFE 999049 6.9 µgFE 999049 8.6 µgFE 999049 10.3 µgFE 999049 12.1 µgGONAL-F 11 µg
Ectopic pregnancyPregnancy, puerperium and perinatal conditions0/420/450/441/440/470/43
Most frequent other events
Most frequent other events
EventFE 999049 5.2 µgFE 999049 6.9 µgFE 999049 8.6 µgFE 999049 10.3 µgFE 999049 12.1 µgGONAL-F 11 µg
HeadacheNervous system disorders4/424/455/443/441/471/43
Abortion spontaneousPregnancy, puerperium and perinatal conditions3/425/452/445/445/471/43
Vaginal haemorrhageReproductive system and breast disorders2/421/454/443/442/471/43
NauseaGastrointestinal disorders2/420/450/441/444/470/43
Pelvic painReproductive system and breast disorders2/420/451/443/442/472/43

Baseline characteristics

Age, Continuous
Age, Continuous(years)FE 999049 5.2 µgFE 999049 6.9 µgFE 999049 8.6 µgFE 999049 10.3 µgFE 999049 12.1 µgGONAL-F 11 µgTotal
Mean33.6 ± 2.2432.3 ± 3.5132.8 ± 2.4432.3 ± 3.2132.6 ± 2.9732.4 ± 3.0432.7 ± 2.95
Sex: Female, Male
Sex: Female, Male(Participants)FE 999049 5.2 µgFE 999049 6.9 µgFE 999049 8.6 µgFE 999049 10.3 µgFE 999049 12.1 µgGONAL-F 11 µgTotal
Female424544444743265
Male0000000
08

Study locations

8 sites
  • UZ Brussel
    Brussels, Belgium
  • UZ Gent
    Gent, Belgium
  • ICF CUBE
    Prague, Czechia
  • Rigshospitalet
    Copenhagen, Denmark
  • IU Dexeus
    Barcelona, Spain
  • IVI Madrid
    Madrid, Spain
  • IVI Sevilla
    Sevilla, Spain
  • IVI Valencia
    Valencia, Spain
09

References and documents

Publications

  • Arce JC, Larsson P, Garcia-Velasco JA. Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU/day follitropin alfa. Reprod Biomed Online. 2020 Oct;41(4):616-622. doi: 10.1016/j.rbmo.2020.07.006. Epub 2020 Jul 15. PubMed 32819842 ↗
  • Arce JC, Andersen AN, Fernandez-Sanchez M, Visnova H, Bosch E, Garcia-Velasco JA, Barri P, de Sutter P, Klein BM, Fauser BC. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril. 2014 Dec;102(6):1633-40.e5. doi: 10.1016/j.fertnstert.2014.08.013. Epub 2014 Sep 23. PubMed 25256937 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Apr 2012 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 6 years 4 months after primary completion. A results delay was requested in Apr 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2011
First posted
Aug 31, 2011
Start
Sep 2011
Primary completionActual
Apr 2012
CompletionActual
Mar 2013
Results delay requested
Apr 12, 2013
Results first posted
Aug 3, 2018
Last update
Nov 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01426386
Responsible party
Sponsor
First posted
Aug 31, 2011
Start date
Sep 2011
Primary completion
Apr 2012
Completion
Mar 2013
Results posted
Aug 3, 2018
Last update
Nov 17, 2020

Study contacts

Clinical Development Support
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin delta

Start the discussion